Arch Oncology

Arch Oncology on 2023-02-22.

Arch Oncology, a Roche-backed biotech startup, has laid off all its employees after discontinuing development of its anti-CD47 antibody program. The company, based in Brisbane, California, effectively ceased operations, resulting in a 100% reduction of its workforce. This decision, reported in January 2023, reflects the high-risk nature of the biotechnology industry, where startups often pivot or shut down when key drug candidates fail to progress. The move underscores the challenges in targeting the CD47 pathway in oncology.